For research the relationship between the expression of vascular endothelial growth factor (VEGF) and the cell proliferation. The expression of VEGF was evaluated while the cell cycle of hepatoma cell line Hep G2, which was synchronized at G0 phase with serum deprivation, and reinitiated with TPA and blocked with antisense oligonucleotides of c-jun. Results: Hep G2 cell did not express VEGF at G0 phase. TPA could induce the expression of VEGF as well as initiation of cell cycle. The antisense oligonucleotides of c-jun could prohibit the expression of VEGF and arrest the cell cycle at G0 phase. Conclusion: The fact that the expression of VEGF accompanies the initiation of cell cycle suggests that they be regulated by the same singnal pathway, the expression of VEGF may be a marker indicating the proliferation of hepatoma cells.
目的 探討射頻消融術在無法實施手術的原發性肝癌患者中的臨床應用效果。方法 回顧性分析2007年9月至2011年3月期間我院收治的58例由于各種原因無法手術治療的大肝癌（＞5cm）并接受射頻消融治療患者的臨床資料，射頻消融前后結合超聲造影的方法，術后隨訪并定期復查血清甲胎蛋白水平和超聲造影或者肝臟增強CT。結果 58例中無一例發生與射頻消融相關的死亡，22例達到完全消融（37.9%，22/58）。共51例（87.9%，51/58）獲得隨訪，隨訪至2012年5月，隨訪時間（12.6±6.4）個月（2～21個月），隨訪12個月以上患者有20例（39.2%，20/51），有10例（19.6%，10/51）無腫瘤復發或者轉移的跡象。22例達到完全消融的患者無瘤生存時間為（13.6±10.4）個月（3～21個月）；36例未能達到完全消融的患者中，有19例隨訪期間死亡，生存時間（8.3±6.1）個月（4～16個月）。結論 由于各種原因不能接受手術的大肝癌患者，射頻消融作為一種有效、安全治療方法，部分能達到完全消融的效果，而部分作為姑息性治療手段，能一定程度上減輕患者的疼痛，達到提高生活質量的目的。
目的 探討臨床治療原發性肝癌合并門靜脈癌栓的有效方法及療效。方法 對我院2008年1月至2010年1月期間收治的29例原發性肝癌合并門靜脈癌栓患者的臨床資料進行回顧性分析,并按治療方法的不同將患者分為經動脈導管栓塞術（TAE）治療組和TAE＋門靜脈灌注化療治療組，比較2組患者的治療效果。結果 TAE治療組治療有效率、門靜脈癌栓縮小率和AFP轉陰率分別為43.75%、18.75%和37.50%，TAE＋門靜脈灌注治療組分別為76.92%、61.54%和61.54%，2組比較后者優于前者（P＜0.05）。TAE＋門靜脈灌注治療組患者治療后半年及1年生存率高于TAE治療組（P＜0.05）。TAE治療組患者生存時間為４～18個月，中位生存期為8個月；TAE＋門靜脈灌注治療組患者生存時間為5～18個月，中位生存期為11個月。結論 TAE＋門靜脈灌注化療是一種安全可行的治療方法，可延長原發性肝癌合并門靜脈癌栓患者的生存時間。
Objective To analyze the disease burden of liver cancer caused by nonalcoholic steatohepatitis (NASH) among the Chinese population by utilizing the latest global burden of disease (GBD) 2021 data, and conduct a comparative analysis with the global situation, so as to provide references and lessons for the formulation of public health policies and disease management plans in China. Methods GBD 2021 database publicly released in May 2024 was searched and relevant disease burden data of liver cancer caused by NASH in China and globally from 1990 to 2021 was sorted out. Joinpoint regression model was employed to calculate the average annual percentage change (AAPC) of the age-standardized rates of various burden indicators in order to evaluate the changing characteristics of disease epidemiology over time. Meanwhile, Bayesian method was used to predict the number of incidences and deaths of liver cancer caused by NASH in China and globally from 2022 to 2045. Results Compared with 1990, in 2021, the number of incidences, prevalence, deaths, disability-adjusted life years, age-standardized incidence rate and age-standardized prevalence rate of liver cancer caused by NASH in the overall, male and female populations in China and globally all increased. Moreover, in 1990 and 2021, all the burden indicators of the Chinese male population were higher than those of the female population in the corresponding years. The overall trend analysis showed that during the 32 years from 1990 to 2021, the age-standardized incidence rate [AAPC=0.44%, 95%CI (0.35%, 0.53%), P<0.001] and the age-standardized prevalence rate [AAPC=0.92%, 95%CI (0.73%, 1.11%), P<0.001] of liver cancer caused by NASH in the overall population in China both showed a significant upward trend. In addition, in 1990 and 2021, the age-standardized rates of all the burden indicators of the overall population in China were higher than the global levels in the corresponding years. The prediction results of the Bayesian model showed that from 2022 to 2045, the number of incidences and deaths of liver cancer caused by NASH in the overall, male and female populations in China and globally will generally show an upward trend. Conclusions The disease burden of liver cancer caused by NASH in China and globally is generally on the rise. In order to curb the increasing disease burden, it is necessary to formulate relevant public health policies and disease management plans in a timely manner.